Fig. 5: Expression and activation levels of qualifying and exploratory biomarkers in the stroma of responders and non-responders. | npj Precision Oncology

Fig. 5: Expression and activation levels of qualifying and exploratory biomarkers in the stroma of responders and non-responders.

From: AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Fig. 5: Expression and activation levels of qualifying and exploratory biomarkers in the stroma of responders and non-responders.

Unsupervised hierarchical clustering analysis using Ward’s method displays kinases and their substrates in the microdissected stroma surrounding the tumor cells collected from 17 of the 20 evaluable patients. RPPA relative intensity values are displayed on a scale ranging from red to blue, where red indicates high levels and blue indicates low levels of expression/activation. On the x-axis are listed proteins measured by RPPA; on the y-axis patients’ outcomes are displayed; samples were color-coded based on response rates where blue indicates responders (CR, PR, and SD) and red non-responders (PD). Members of the PI3K/AKT/mTOR signaling pathway and HER family co-clustering together are highlighted on the x-axis in red and blue, respectively.

Back to article page